| abstract |
The invention provides an injectable bone repairing agent, comprising sodium alginate, chitosan, hydroxyapatite, mannitol, rBMP2, acetate buffer and double distilled water, and the BMP2 content in the injectable bone repairing agent is 0.5 ‑2mg/ml. The injectable repair agent is used in conjunction with the porcine-derived fibrin adhesive, and is sprayed onto the target wound through a special applicator. The porcine-derived fibrin adhesive is a hemostatic biological product that assists conventional surgical operations. At the same time, it can be hydrolyzed and absorbed by its own enzymes in the human body within 15 days. The injectable repair agent and the porcine-derived fibrin adhesive can evenly and well adhere to the wound without being affected and functioning. |